Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 1,866
Quick answer
1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10533159
Pichinde virus reverse genetics systems and methods of use
granted -
US 10533016
Compounds that participate in cooperative binding and uses thereof
granted -
US 10532992
Prodrugs of urolithins and uses thereof
granted -
US 10533040
Colon and pancreas cancer peptidomimetics
granted -
US 10532050
Formulations of oxabicycloheptanes and oxabicycloheptenes
granted -
US 10532106
Bicyclic peptide ligands specific for MT1-MMP
granted -
US 10532096
Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
granted -
US 10532079
Extracts and beverages containing 2,5-piperazinedione, 3,6-bis(phenylmethyl)-, (3S,6S)-
granted -
US 10532059
Steroid hormone pharmaceutical composition
granted -
US 10533053
Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor
granted -
US 10532056
Therapeutic compositions, combinations, and methods of use
granted -
US 10532040
Methods of treating cancer with herbacetin
granted -
US 10533174
Splice-region antisense composition and method
granted -
US 10532032
Rolled collagen carrier
granted -
US 10533186
Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
granted -
US 2020016151
NOVEL NAPHTHYLENYL COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS
granted -
US 2020017529
NOVEL THIENOTHIOPHENE COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS
granted -
WO 2020012244
TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AU MOYEN DE BRAZIKUMAB
granted -
US 10538530
Vasopressin receptor antagonists and products and methods related thereto
granted -
US 10537642
Pharmaceutical compositions comprising meloxicam
granted -
US 10537635
Detection of arginine methylation of EGFR for prediction of resistance to therapy
granted -
US 10537611
Methods of treating lung cancer
granted -
US 10537596
Bone marrow adipose portion isolation device and methods
granted -
US 10537581
Vaginal inserted estradiol pharmaceutical compositions and methods
granted -
US 10537577
Compounds and compositions for ossification and methods related thereto
granted -
US 10537565
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
granted -
US 10537560
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
granted -
US 10537553
Methods of treating muscular dystrophy
granted -
US 10537537
Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
granted -
US 10537529
Cell-free methods of producing vault particles and vault particles resulting therefrom
granted -
US 10537528
Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
granted -
US 10538513
Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
granted -
US 10537594
Targeted transplantation of mitochondria to hepatocytes
granted -
US 10538570
Targeted and modular exosome loading system
granted -
US 10537535
Histone deacetylase inhibitors
granted -
US 10538590
Photosensitizing antibody-fluorophore conjugates
granted -
US 10538579
Bispecific pertussis antibodies
granted -
US 10537595
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 10538787
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 10538765
Organic compositions to treat EPAS1-related diseases
granted -
US 10538762
Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat
granted -
US 10538749
Mutant OPAA enzymes with increased catalytic efficiency on cyclosarin
granted -
US 10538532
Hepatitis B antiviral agents
granted -
US 10537645
Protein-polymer-drug conjugates
granted -
US 10538763
Compounds and methods for modulation of DUX4
granted -
US 2020024256
TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
granted -
US 10544467
Solid tumor methylation markers and uses thereof
granted -
US 10544232
Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
granted
Frequently asked questions
How many pharma patents expire in 2040?
1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.